New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin

Hypertension

Volumn 61, Issue 5, 2013, Pages 1075-1082

  Krop, Manne ^a   Lu, Xifeng ^a   Verdonk, Koen ^a   Schalekamp, Maarten A D H ^a   Van Gool, Jeanette M G ^a   McKeever, Brian M ^b   Gregg, Richard ^b   Danser, A H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Vitae Pharmaceuticals   (United States)

Author keywords

conformational changes; hypertension; prorenin; renin; renin inhibitor

Indexed keywords

ALISKIREN; PLACEBO; PRORENIN; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG; VTP 27999;

ADULT; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN UNFOLDING;

ADULT; AMIDES; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUMARATES; HALF-LIFE; HUMANS; IMMUNOASSAY; MALE; PIPERIDINES; PROTEIN BINDING; PROTEIN UNFOLDING; RENIN;

EID: 84876689810     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00967     Document Type: Article

References (20)

1. Michaud A, Bur D, Gribouval O, Muller L, Iturrioz X, Clemessy M, Gasc JM, Gubler MC, Corvol P. Loss-of-function point mutations associated with renal tubular dysgenesis provide insights about renin function and cellular traffcking. Hum Mol Genet. 2011;20:301-311.
2. Morales R, Watier Y, Böcskei Z. Human prorenin structure sheds light on a novel mechanism of its autoinhibition and on its non-proteolytic activation by the (pro)renin receptor. J Mol Biol. 2012;421:100-111.
3. Schalekamp MADH, Derkx FHM, Deinum J, Danser AHJ. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens. 2008;26:928-937.
4. Krop M, van Gool JM, Day D, Hollenberg NK, Jan Danser AHJ. Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment. J Hypertens. 2011;29:2138-2146.
5. Batenburg WW, de Bruin RJA, van Gool JM, Müller DN, Bader M, Nguyen G, Danser AHJ. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28:1151-1157.
6. Derkx FHM, Deinum J, Lipovski M, Verhaar M, Fischli W, Schalekamp MADH. Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specifc monoclonal antibody. J Biol Chem. 1992;267:22837-22842.
7. Krop M, Garrelds IM, de Bruin RJA, van Gool JM, Fisher ND, Hollenberg NK, Danser AHJ. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension. 2008;52:1076-1083.
8. Ménard J, Guyene TT, Peyrard S, Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens. 2006;24:529-534.
9. Jia L, Simpson RD, Yuan J, et al. Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility. ACS Med Chem Lett. 2011;2:747-751.
10. Deinum J, Derkx FHM, Schalekamp MADH. Probing epitopes on human prorenin during its proteolytic and non-proteolytic activation. Biochim Biophys Acta. 1998;1388:386-396.
11. Galen FX, Devaux C, Atlas S, Guyenne T, Ménard J, Corvol P, Simon D, Cazaubon C, Richer P, Badouaille G. New monoclonal antibodies directed against human renin. Powerful tools for the investigation of the renin system. J Clin Invest. 1984;74:723-735.
12. Campbell DJ, Nussberger J, Stowasser M, Danser AHJ, Morganti A, Frandsen E, Ménard J. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem. 2009;55:867-877.
13. Saris JJ, Derkx FH, De Bruin RJA, Dekkers DHW, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser AHJ. High-affnity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol Heart Circ Physiol. 2001;280:H1706-H1715.
14. Rahuel J, Priestle J P, Grütter MG. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. J Struct Biol. 1991;107:227-236.
15. Danser AHJ, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension. 2005;46:1069-1076.
16. Fisher ND, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199-3205.
17. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698-705.
18. Cohen NC. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. Chem Biol Drug Des. 2007;70:557-565.
19. Batenburg WW, Danser AHJ. (Pro)renin and its receptors: pathophysi-ological implications. Clin Sci. 2012;123:121-133.
20. Batenburg WW, Lu X, Leijten F, Maschke U, Müller DN, Danser AHJ. Renin-and prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur? Hypertension. 2011;58:1111-1119.